Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
decitabine + panitumumab
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Decitabine + panitumumab is an investigational combination therapy consisting of decitabine, a hypomethylating agent, and panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Decitabine acts as a DNA methyltransferase inhibitor, leading to hypomethylation of DNA and potential reactivation of tumor suppressor genes. Panitumumab binds to EGFR on the surface of cancer cells, blocking ligand-induced activation and downstream signaling pathways involved in cell proliferation and survival. This combination has been studied primarily in patients with metastatic colorectal cancer (mCRC) who have wild-type KRAS tumors. The rationale for combining these agents is that epigenetic modulation by decitabine may enhance sensitivity to anti-EGFR therapy in resistant tumors[1][2].
- Other names
- decitabine + panitumumab
02
Targets
EGFR (Epidermal growth factor receptor)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on decitabine + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on decitabine + panitumumab.